Noile-Immune Biotech Inc. (4893.T)
JPY 137.0
(-0.72%)
JPY 137.0
(-0.72%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.55 Billion JPY | -22.89% |
| 2022 | -4.52 Billion JPY | -9.19% |
| 2021 | -4.14 Billion JPY | -62.5% |
| 2020 | -2.54 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -5.24 Billion JPY | 5.67% |
| 2024 Q2 | -4.94 Billion JPY | 5.6% |
| 2023 Q3 | -5.65 Billion JPY | 5.0% |
| 2023 FY | -5.55 Billion JPY | -22.89% |
| 2023 Q1 | -3.87 Billion JPY | 14.36% |
| 2023 Q2 | -5.95 Billion JPY | -53.77% |
| 2023 Q4 | -5.55 Billion JPY | 1.77% |
| 2022 Q4 | -4.52 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 847.98% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -389.944% |
| GNI Group Ltd. | -17.93 Billion JPY | 69.021% |
| Linical Co., Ltd. | -4.46 Billion JPY | -24.475% |
| Trans Genic Inc. | -221.16 Million JPY | -2411.966% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | -26.437% |
| Soiken Holdings Inc. | -4.79 Billion JPY | -15.985% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 487.551% |
| AnGes, Inc. | -3.79 Billion JPY | -46.289% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -1220.247% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 122.305% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -1015.256% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -1091.321% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | -105.3% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -194.232% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -465.671% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | -63.546% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -437.013% |
| Kidswell Bio Corporation | 343.58 Million JPY | 1716.958% |
| PeptiDream Inc. | 3.29 Billion JPY | 268.764% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -471.225% |
| Ribomic Inc. | -2.09 Billion JPY | -164.589% |
| SanBio Company Limited | -3.78 Billion JPY | -46.599% |
| Healios K.K. | -2.19 Billion JPY | -153.685% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -487.991% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | -111.714% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -292.057% |
| StemRIM | -8.41 Billion JPY | 33.939% |
| CellSource Co., Ltd. | -4.68 Billion JPY | -18.623% |
| FunPep Company Limited | -1.79 Billion JPY | -209.789% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | -160.038% |
| Stella Pharma Corporation | -1.11 Billion JPY | -396.308% |
| TMS Co., Ltd. | -3.44 Billion JPY | -61.192% |
| Cuorips Inc. | -5.56 Billion JPY | 0.096% |
| K Pharma,Inc. | -3.26 Billion JPY | -70.086% |
| Takara Bio Inc. | -32.2 Billion JPY | 82.748% |
| ReproCELL Incorporated | -2.93 Billion JPY | -89.03% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -740.549% |
| StemCell Institute Inc. | -2.83 Billion JPY | -95.847% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | -168.866% |
| CellSeed Inc. | -2.01 Billion JPY | -176.122% |